New Jersey AG investigating Amgen
Pharma Compliance Alert, January 23, 2008
New Jersey Attorney General (AG) Anne Milgram is investigating whether Amgen violated patient confidentiality laws in order to market Enbrel, according to an article in The New York Times.
The investigation stems from allegations by two former Amgen sales representatives, who claim they were told to look through patient records to find people who might be candidates for Enbrel. More information about the allegations appears in the January 16 issue of Pharma Compliance Alert.
A state-issued subpoena calls for Amgen to deliver all documents and information about the marketing, sale, and prescription of Enbrel between July 2002 and the present, according to a press release from the AG.
Comments
0 comments on “New Jersey AG investigating Amgen ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- Capturing all necessary codes for IUD insertion and removal can be challenging
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- HIPAA Q&A: Level of encryption needed for email
- OB services: Coding inside and outside of the package
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q/A. One injection code or two?
- What does case-mix index mean to you?
- ED-to-inpatient transfers are flawed with safety gaps
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Searched